Jul 9 2012
SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. (Nasdaq: SRDX) and a market leader for in vitro diagnostic assay components, is pleased to announce it will launch BioFX® TMB Extended Range HRP Microwell Substrate (TMBX) at the American Association for Clinical Chemistry show in Los Angeles, CA from July 17-19, 2012.
“SurModics is committed to using its diagnostic history and expertise to develop and improve products, including custom formulation options to better serve our customers.”
Use of BioFX TMBX in a quantitative assay (i) can increase the assay's upper limit of quantitation and (ii) maintain the detection limits and analytical sensitivity achieved with other SurModics TMB substrates. TMBX also improves the reproducibility of the assay through lower backgrounds and better control of assay timing. TMBX is our slowest kinetic option of TMB substrates for extended dynamic range and improved reproducibility within.
"This newest addition to SurModics' line of TMB substrate products further demonstrates the flexibility of our capabilities to support the in vitro diagnostics industry and its extended dynamic range needs," said Gary Maharaj, president and chief executive officer of SurModics. "SurModics is committed to using its diagnostic history and expertise to develop and improve products, including custom formulation options to better serve our customers."
Source SurModics, Inc.
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes